What is Kiora Pharmaceuticals, Inc. (KPRX)?

Kiora Pharmaceuticals, Inc. (KPRX) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of KPRX?

The current price of KPRX is $1.56. Prices are updated in real time on Stocks360.

What is KPRX's price-to-earnings (PE) ratio?

KPRX's trailing twelve-month PE ratio is -0.62, based on current price and earnings per share data available on Stocks360.

What is KPRX's market capitalization?

KPRX's market capitalization is $6,902,048.00, placing it in the small-cap tier.

Kiora Pharmaceuticals, Inc. (KPRX)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$1.56

Market Cap

$6.90M

PE (TTM)

-0.62

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-0.39

Day Range

$1.55 – $1.83

52-wk Range

$1.55 – $2.91

Avg Volume

N/A

Volume

100.65K

Kiora Pharmaceuticals, Inc. (KPRX) is a publicly traded company in the Healthcare sector. Latest price: $1.56. Market cap $6.90M. Trailing PE -0.62. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $2.31 2026-10-30 · $1.56 (-32.47%)

Earnings

Most Recent

Aug 7, 2026

EPS $-0.34 vs est. $-0.47

Beat by $0.13

Next Earnings

Nov 6, 2026

EPS estimate $-0.38

Proprietary Signals

Signal snapshot temporarily unavailable.

About Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.62×
P/S (TTM)	0.00×
P/B	0.57×
P/FCF (TTM)	-0.80×
EV / EBITDA	-0.01×
EV / Sales	0.00×
Earnings Yield	-114.00%
Free Cash Flow Yield	-124.80%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$158.54K
Net Income (TTM)	-$7.87M
Free Cash Flow (TTM)	-$8.61M
Net Debt	-$6.74M
Working Capital	$18.89M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-63.39%
Return on Invested Capital	-53.16%